

**Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial**

Authors :

Sr. No.	Name	Affiliation	Email ID
1.	Prof. Dr. Suresh B. Patankar*	AMAI Charitable Trust, Pune	<a href="mailto:sureshpatankarace@gmail.com">sureshpatankarace@gmail.com</a>
2.	Dr. Hrishikesh Rangnekar	Quest Clinical Services, Pune	<a href="mailto:h.rangnekar@questclinicalservices.co.in">h.rangnekar@questclinicalservices.co.in</a> <a href="mailto:dr.rangnekar@gmail.com">dr.rangnekar@gmail.com</a>
3.	Dr. Kalpana Joshi	Dept. of Biotechnology, Sinhgad College of Engineering, Pune	<a href="mailto:kalpanajoshi1788@gmail.com">kalpanajoshi1788@gmail.com</a>
4.	Dr. Kishor Suryawanshi	YCM Hospital, Pune	<a href="mailto:drkishorsuryawanshi@gmail.com">drkishorsuryawanshi@gmail.com</a>
5.	Dr. Pravin Soni	YCM Hospital, Pune	<a href="mailto:drpravinsoni18@gmail.com">drpravinsoni18@gmail.com</a>
6.	Dr. Anupama Gorde	Sinhgad Institute of Dental Sciences, Pune	<a href="mailto:drpatankar02@yahoo.in">drpatankar02@yahoo.in</a>
7.	Dr. Tejas Shah	Krsnaa Diagnostics Pvt. Ltd. Pune	<a href="mailto:sktejas09@gmail.com">sktejas09@gmail.com</a>
8.	Mr. Sagar Patankar	AMAI Charitable Trust, Pune	<a href="mailto:sagarpatankar87@gmail.com">sagarpatankar87@gmail.com</a>
9.	Dr. Diwakar Jha	SHRIPAD Medisearch Pvt. Ltd., Pune	<a href="mailto:drdjha@gmail.com">drdjha@gmail.com</a>
10.	Dr. Rajesh Raje	AMAI Charitable Trust, Pune	<a href="mailto:researchhace2@gmail.com">researchhace2@gmail.com</a>

Corresponding Author\*

1     **Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to**  
2                   **moderate COVID-19: A randomized, double-blind, placebo-controlled trial**

3     **ABSTRACT**

4     **Objective:** To assess the efficacy and safety of polyherbal formulation (designated as IP) in  
5     comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate  
6     novel corona virus disease 2019 (COVID-19)

7     **Methods:** Laboratory proved patients of mild to moderate COVID-19 disease were randomized to  
8     either placebo or IP as an add-on to SoC. Using quantitative reverse transcription-polymerase chain  
9     reaction (qRT-PCR), we assessed the effect on viral load (VL). Change in immunological parameters  
10    such as blood lymphocyte subset, serum immunoglobulin was determined. The clinical improvement  
11    was assessed using a numerical rating scale (NRS) and WHO ordinal scale. Patients were followed for  
12    30 days after randomization.

13    **Results:**In total, 72 patients were randomized to either placebo (n=33) and IP (n=39). Fifty-two  
14    patients (n=21 in placebo and n=31 in IP arm) had qRT-PCR on day 0 and day 4. There was  
15    significant reduction in VL in IP arm (from 662081 copies/mL on day 0 to 48963 copies/mL on day 4;  
16     $p=0.002$ ) but not in the placebo arm (from 385670 copies/mL on day 0 to 66845 copies/mL on day 4,  
17     $p=0.106$ ). Change in the NRS score and WHO ordinal scale score was significant in both treatment  
18    arms. However, the difference between the two groups was statistically significant in favour of drug  
19    group, . The increase in Th1 response was significant in the IP arm ( $p=0.023$ ) but not in the placebo  
20    arm ( $p=0.098$ ), thus implying immunomodulatory activity in the drug. No safety concerns were  
21    observed in any of the trial participants.

22    **Conclusion:** This study finds that polyherbal formulation reduces viral load and contributes to  
23    immunomodulation and improvement in clinical conditions when used as add-on to the standard care

24 in patients with mild to moderate COVID-19 without any side effects. These findings need to be  
25 further confirmed in a large, prospective, randomized study.

26 **Keywords:** COVID-19, herbal medication, viral load, immuno modulation.

27

## 28 INTRODUCTION

29 Novel coronavirus disease 2019 (COVID-19) pandemic is a significant contributor to morbidity and  
30 mortality in affected individuals. World Health Organization, as of 23 April 2021, reports 144,358,956  
31 confirmed cases of COVID-19, including 3,066,113 deaths [1]. Since its first identification in  
32 December 2019, there is now a fair understanding of the COVID-19 disease pathogenesis. Hyper  
33 stimulated immune response causing systemic inflammatory response syndrome or “cytokine storm”  
34 is known to be implicated in progression to severe COVID-19 [2,3]. Such immune response correlates  
35 linearly with the viral load that in turn correlates with disease severity [4,5]. Modulating the immune  
36 response in COVID-19 is now an established treatment approach. The RECOVERY trial showed that  
37 dexamethasone 6 mg once daily for ten days significantly lowered 28-day mortality in hospitalized  
38 COVID-19 patients [6]. Also, treatment with specific interleukin -6 inhibitor tocilizumab did not  
39 improve survival but reduced the likelihood of progression to the composite outcome of mechanical  
40 ventilation or death [7]. With Itolizumab, an anti-CD6 humanized monoclonal antibody with an  
41 immunomodulating action on T effector cells, there was a significant reduction in 30-day mortality  
42 along with significant improvement in clinical immunological, and oxygen parameters [8]. Thus,  
43 modulating immune response can help to improve clinical parameters and mortality outcomes,  
44 especially in hospitalized moderate to severe COVID-19 patients.

45 Herbal formulations have long been assessed for their potential immune modulating effects [9,10]. In  
46 an in-vitro study (*data on file*), we observed that a combination of herbals (IP) such as Ashwagandha

47 (*Withaniasomnifera*), Vidanga (*Embeliaribes*), Guduchi (*Tinospora cordifolia*), Haritaki (*Terminalia*  
48 *chebula*), Aamalaki (*Embllica officinalis*), Shatavari (*Asparagus racemosus*), Yashtimadhu  
49 (*Glycyrrhiza glabra*), Ginger (*Zinziber officinale*), Pippali (*Piper longum*), Shankha Bhasma and  
50 Jasath Bhasma showed antiviral activity against SARS-CoV-2. As the search for potential antiviral  
51 and immune modulating therapy for COVID-19 is ongoing, this could be potentially beneficial.  
52 Therefore, we conducted this randomized, double-blind, placebo-controlled study to determine the  
53 effect of the polyherbal formulation on viral load and immunological parameters and clinical  
54 improvement in mild to moderate COVID-19 disease when used as an add-on to the SoC.

## 55 **MATERIALS AND METHODS**

### 56 ***Design and Population***

57 This study was a double-blind, randomized, placebo-controlled trial to assess the safety and efficacy  
58 of polyherbal drug formulation (designated as IP) in patients with mild to moderate COVID-19. The  
59 study was conducted at a single center in Pune, Maharashtra, India. We enrolled adults of age 18  
60 years and above, diagnosed with laboratory-proven COVID-19 disease of mild to moderate severity  
61 who were admitted to the hospital as per the isolation protocol. Pregnant and lactating females, any  
62 respiratory symptoms of >7 days, patients with known pathology affecting the respiratory system,  
63 diagnosed hematological disorders, patients with a terminal illness, any other condition which in the  
64 view of the investigator would interfere with the general clinical well-being of the participant and  
65 those not willing to participate in the study were excluded. The trial was conducted as per the ethical  
66 principles of the Declaration of Helsinki, good clinical practice recommendations and applicable local  
67 regulatory guidelines. The study was approved by the Board of Research Studies (BORS) and  
68 Institutional Ethics Committee of Yashwantrao Chavan Memorial Hospital, Pimpri, Pune. Informed  
69 consent was obtained from all the participants before enrolment. The study was registered with the

70 clinical trial registry of India (CTRI/2020/07/026570).The study protocol was published in a peer-  
71 reviewed journal [11].

## 72 ***Study treatments and follow-ups***

73 Patients with a known positive status of RT-PCR for SARS-CoV-2 disease were screened for the  
74 study. Eligible and consenting patients were enrolled. Patients were randomized using computer-  
75 generated randomization codes to receive either IP or placebo as an add-on to the recommended  
76 standard care (SoC) for COVID-19. IP in the title was a combination of IP1 and IP2, having the  
77 following ingredients. IP1: Shunthi (*Zinziber officinale*), Vidanga (*Embelia ribes*), Yashtimadhu  
78 (*Glycyrrhiza glabra*), Shankhabhasma and Jasath Bhasma. IP2 contains: Haritaki (*Terminalia*  
79 *chebula*), Guduchi (*Tinospora cordifolia*), Shatavari (*Asparagus racemosus*), Aamalaki (*Emblica*  
80 *officinalis*), Pippali (*Piper longum*), Ashwagandha (*Withania somnifera*) and Jasath Bhasma. The  
81 investigational products were manufactured per API guidelines. Patients were advised to take one  
82 capsule, two times a day (of each IP1 and IP2) or placebo, after meals. Patients received a prepacked  
83 carton of study treatment for a total duration of 30 days. Capsule IP1 and IP2 were given for the first  
84 15 days, and last 15 days they were given only IP2. Patients receiving placebo also received 2  
85 capsules twice a day for first 15 days and for next 15 days, one capsule twice a day (Image 1). All the  
86 patients continued their routine diet and physical activity and other prescribed treatment as per Indian  
87 Council of Medical Research (ICMR) and World Health Organization (WHO) guidelines in  
88 circulation at the time of study conduct.

89 During baseline visit (Day 0) nasopharyngeal swab was taken for qRTPCR, numerical rating scale  
90 (NRS) was filled for clinical status and the blood was withdrawn for various immunological  
91 inflammatory and safety markers. Patients had three follow-ups during the 30-day treatment period.  
92 First follow-up visit was done at day 4±1. qRTPCR , NRS was repeated at this visit and any clinical  
93 adverse events were recorded . Second follow-up was done clinically or telephonically (if they were

94 discharged) on day 15±2 to record any clinical deterioration in clinical condition and to record  
95 adverse effects if any. Last follow-up was at day 30±2 to document clinical condition, adverse effects  
96 and perform laboratory investigations. In this last follow-up, study personnel visited patients in their  
97 homes to avoid their repeat visit to site as it was active COVID-19 hospital. Patients were asked to  
98 visit any time if they observed any deterioration in clinical condition or had developed any untoward  
99 reactions.

#### 100 *Quantitative estimation of viral load using qRT-PCR*

101 Three viral loci RdRP, N gene and E gene and a human gene as internal control (RNaseP) were  
102 detected using GenePath Diagnostics' indigenously developed qRT-PCR assay, CoViDx One v2.1.1  
103 keeping appropriate controls and standards. Ten micro litres of extracted nucleic acid was used as an  
104 input for the qRT-PCR. Quantitative estimation for each genomic target was performed using  
105 standards, for which the number of genome copies were already known. The threshold cycle (Ct  
106 value) for each genomic target was extrapolated to the viral load of standards to estimate the number  
107 of copies/uL which were then converted to copies/mL for each gene for each sample. Average number  
108 of copies/ ml was calculated for each sample that accounts for the approximate viral load in the  
109 sample. Ct values for control human gene (RNaseP) ensured the adequacy of sample and served as  
110 control for nucleic acid extraction and nucleic acid amplification.

111 On the day of first encounter with patients, they were subjected to thorough clinical and laboratory  
112 investigations. After signing of informed consent, their demographic details, and clinical parameters  
113 were recorded. Oxygen saturation was assessed using pulse oximeter. We investigated viral load (VL)  
114 with quantitative RTPCR for COVID-19, and blood was drawn for lymphocyte subset analysis  
115 (absolute neutrophil count, absolute lymphocyte count, TH1, TH2, Treg cells, NK Cells and CD  
116 markers such as CD3, CD4, CD3: CD8 ratio) as well as serum IgG and IgM levels (not specific to  
117 COVID-19). Liver function tests and renal function tests were performed as a part of safety

118 assessment.. Blood investigations were repeated on day 30 for immunological markers, and for safety  
 119 assessments. We performed all the tests at a single accredited laboratory .

120 ***Outcome measures***

121 Primary efficacy outcome measure was change in viral load. Secondary efficacy outcome measures  
 122 were change in disease severity score and change in immunological and inflammatory markers.  
 123 Numerical Rating Scale (NRS) was used for overall disease severity. 0 was considered for normal, 1  
 124 to 3 for mild, 4 to 6 for moderate and 7 to 10 for severe severity of the disease. Patients were asked to  
 125 rate the disease severity on the NRS. Also, change in immunological parameters such as lymphocyte  
 126 subset analysis (TH1, TH2, Th17),NK Cells and CD markers, serum IgG and IgM levels and Covid19  
 127 antibodies were assessed. Inflammatory and other markers like C - reactive protein and D-Dimer, Sr.  
 128 Ferritin were assessed in a small portion of enrolled subjects. Primary safety measure was incidence  
 129 of adverse reactions (clinical and/or laboratory parameters).

**Statistical analysis:** Sample size:

Two sided significance level ( 1 alpha)	95
Power ( 1-beta. % chance of detecting)	80
Ratio of sample size, Unexposed/ exposed	1
% of Unexposed with outcome	5
% of Exposed with outcome	35
Odds ratio	10
Risk/ Prevalence ratio	7
Risk/ Prevalence	30

	<b>Kelsey</b>	<b>Fleiss</b>
Sample Size Exposed	28	27
Sample Size Non exposed	28	27
<b>Total Sample Size</b>	<b>56</b>	<b>54</b>

**References:**

Kelsey et al, Methods in Observational Epidemiology, 2<sup>nd</sup> edition, table 12-15, Fleiss, Statistical Methods For Rates and Proportions, formulas 3.18 and 3.19.

**Results are rounded up to the nearest integer**

137 **Results from OpenEpi, Version 3, open source calculator –SSC cohort.**

138 Considering drop-outs, 72 patients were enrolled.Data was entered in to the Microsoft excel sheet  
 139 version 2016 and was analyzed with SPSS software. Categorical variables were presented as  
 140 frequency and percentage. Statistical comparisons of categorical data were done with Chi square test

141 or Fischer exact test. For continuous variables, normal distribution was assessed by plotting the  
142 histograms. Normally distributed data was presented using mean and standard deviations (SD) and  
143 non-normally distributed data presented as median (Interquartile range (IQR) 25-75). Student t-test  
144 and Mann-Whitney U test were applied accordingly to test the statistical differences in continuous  
145 independent variables. For before and after analysis, we used paired t test and Wilcoxon signed rank  
146 sum test to determine the statistical significance. P value <0.05 was considered significant for all  
147 comparisons.

## 148 **RESULTS**

### 149 *Participant enrolment flow*

150 Between August and September 2020, we screened 92 patients of which 72 were randomized to either  
151 placebo (n=33) or IP (n=39). Figure 1 shows study flow of the participant. Overall, 66 patients  
152 completed the 30-day follow-up (placebo n= 31; IP n=35).

### 153 *Demographic parameters* (Table no. 1)

154 Mean age was 43 years and 47 years in placebo and IP group (p=0.336). There was no difference in  
155 proportion of males and females in two groups (p=0.150).

### 156 *Effect on Viral Load (VL)* (Table no. 2)

157 Overall, 52 patients had undergone qRT-PCR on day 4 (31 in drug arm, 21 in placebo arm). IP  
158 treatment was associated with significant reduction in median VL (from 662081 virus copies/mL  
159 (IQR: 56904 to 19485712) on day 0 to 48963 copies/mL (IQR: 8774 to 1248257) day 4;  $p=0.002$ ). In  
160 placebo group also, there was reduction in VL but it was non-significant (from 385670 copies/mL  
161 (IQR: 30807 to 131511846) on day 0 to 66845 copies/mL (IQR: 11978 to 836124.5) on day 4  
162 ( $p=0.106$ )). Standard of care was continued in both the groups.

### 163 *Clinical Assessment* (Table No. 3)



164 In the IP arm, there was significant reduction in NRS from day 0 to day 4 (4.3 ( $\pm 1.13$ ) 1.74( $\pm 1.03$ ),  
165  $p < 0.0001$ ). In Placebo arm as well, there was significant reduction in NRS score (4.26 $\pm 1.09$  to  
166 3.16 $\pm 1.03$ ,  $p < 0.0001$ ). Baseline scores of both the groups were similar, with P value 0.78; the  
167 difference between drug and placebo arm of 'after' was statistically highly significant. Later, upon  
168 WHO ordinal scale was available, and retrospectively the scores were assigned to the patients'  
169 condition, on day 0 and 4, IP arm was at 1.63 ( $\pm 0.84$ ) and 1.03 ( $\pm 0.45$ ) respectively with p value  
170 0.0001; whereas, for placebo, these values were 1.71 ( $\pm 0.78$ ) and 1.26 ( $\pm 0.63$ ) with p value 0.03. P  
171 value for drug arm was highly significant ( $> 0.01$ ).

#### 172 ***Blood Biomarkers for immunity and inflammation***

173 Changes in the inflammatory and immunological parameters are shown in Table 4, between day 0 and  
174 day 30. There was significant increase in absolute B cell count, absolute T cell count, absolute CD3,  
175 CD4 and T helper cells as well as in the ratio of absolute CD3 and CD8 cells in both IP and placebo  
176 arm. Change in absolute NK cell count was significant in placebo arm ( $p = 0.020$ ) but not in drug arm  
177 ( $p = 0.067$ ). However, the magnitude of change was higher with IP than the placebo. The increase in  
178 Th1 response was significant with IP treatment ( $p = 0.023$ ) but not with the placebo treatment  
179 ( $p = 0.098$ ). The IgG antibodies reduced significantly in both placebo and IP arm. However, the effect  
180 on IgM was non-significant in both groups. Covid antibodies were done on day 30. P value was not  
181 significant, however around 20% more antibodies were noted in drug arm than placebo arm. Due to  
182 inadequate sample size for CRP, D Dimer analysis was not feasible, however, average 50% reduction  
183 in CRP was seen in SoC + drug arm whereas increase in the SoC + Placebo arm was seen. Similar  
184 trend was seen for D Dimer also. Less number of patients opted for blood withdrawal during follow-  
185 up visits, and majority of them denied the blood letting.

#### 186 **Safety**

187 There were no serious adverse events in the drug arm. One SAE occurred in placebo (+SoC)  
188 arm, which was ‘prolongation of hospitalization’ due to Covid related pneumonia, which got  
189 resolved later. LFT, RFT were not deranged in any of the patient, confirming safety. No  
190 drug-drug interaction with the SoC was seen.

## 191 **DISCUSSION**

192 Since December 2019, COVID -19 pandemic has been around the globe affecting millions of  
193 individuals with significant contribution in morbidity and mortality. Despite being present for over a  
194 year, definite therapies are limited for COVID-19. Modulating immunological response with steroids  
195 has been found beneficial in hospitalized patients. However, in a large majority of patients who have  
196 mild to moderate disease, effective treatment is necessary to prevent disease progression as well as  
197 shedding of the virus to lower the transmission rates. Thus, reducing the viral load may assist in  
198 achieving this objective. Viral load independently correlates with the risk of intubation and in-hospital  
199 mortality [12,13]. We observed that IP was associated with significant reduction in viral load at day 4.  
200 Reducing the viral load can help in early symptom recovery. It was evident as NRC was significantly  
201 reduced.

202 Anti-viral activity of IP therefore can be helpful in early recovery of mild to moderate COVID-19  
203 patients. Among currently employed antiviral agents, early treatment with favipiravir was reported to  
204 be associated with lower in VL at day 6 In hospitalized patients with COVID-19 [14].

205 Another antiviral agent that is used widely is remdesivir. However, remdesivir did not appear to affect  
206 rates of viral RNA load decline and mortality when compared with placebo in severe hospitalized  
207 COVID-19 patients [15]. Thus, initiating an antiviral agent before the peak viral load might be  
208 necessary. It may be difficult in clinical situation to predict the time of peak VL. In this study, IP was  
209 initiated as soon as individuals were tested positive for COVID-19 which might have helped in early  
210 improvement in clinical NRS score.

211 In addition to lowering VL, modulating immune response is now an established strategy. In  
212 inflammatory response, Th1 pathway is associated with increase in the release of proinflammatory  
213 cytokines like IL-1, IL-2, IL-12, TNF- $\alpha$ , IFN- $\gamma$ , etc. Dysregulated immune response is associated with  
214 development of cytokine storm. Most recent data demonstrated that COVID-19 might affect  
215 lymphocytes, especially T lymphocytes. The absolute number of T lymphocytes, CD4+ T cells, and  
216 CD8+ T cells decreased in infected individuals [16]. Immunomodulatory activity of single plants as  
217 well as polyherbal formulations from Ayurveda are well reported [17]. Modulation of immune  
218 response was evident in our study. Though placebo with SoC also showed significant effect, the  
219 change in Absolute CD3, CD4 and T helper cells was numerically higher with IP treatment. Tregs and  
220 their functions are compromised in severe COVID-19 patients, engendering unrestrained immune cell  
221 activation resulting in damaged lungs in severe COVID-19 patients [18]. There is less reduction of  
222 Tregs in the IP group as compared to the placebo group indicates a good inflammatory control in the  
223 IP group. In severe COVID-19 patients, NK cell number and function is reduced, resulting in  
224 decreased clearance of infected and activated cells, and unchecked elevation of tissue-damaging  
225 inflammation markers. Restoration of NK cell effector functions has the potential to correct the  
226 delicate immune balance required to effectively overcome SARS-CoV-2 infection [19,20]. Though the  
227 statistical significance was not reached, increase in the number of NK cells was higher in IP group  
228 than that of placebo. It probably indicates a potential to preserve and enhance the NK cell function  
229 that might assist in viral clearance.

230 The in-vitro study conducted with study drug with remdesivir used as a positive control for viral  
231 inhibition. Inhibition of virus replication is determined based on the fold change in the Ct value in TS-  
232 treated cells compared to the control. After 24 hours, % inhibition of E-gene was 9.10% and of N  
233 gene, it was 21.93%. After 48 hours, N gene inhibition was same as 24 hours however E gene was

234 further inhibited to 28.43% (*data on file*). Thus, clinical effects of viral load reduction identified with  
235 qRT-PCR are supported by the in-vitro data.

236 Protocol of the study was published in BMC's 'Trials' (2020)21:943. It was for the first time  
237 that any study protocol pertaining to an Ayurveda intervention was published in the BMC  
238 journal. (<https://doi.org/10.1186/s13063-020-04906-x>)

239 At individual level, each ingredient has unique properties and for example, Guduchi (*Tinospora*  
240 *cordifolia*), Haritaki (*Terminalia chebula*), Amalaki (*Eblica officinalis*) has shown efficacy as anti-  
241 viral drugs, as an anti-oxidant, as an immune modulator; for Amalaki, a paper entitled, 'Structure-  
242 based drug designing for potential antiviral activity of selected natural products from Ayurveda  
243 against SARS-CoV-2 spike glycoprotein and its cellular receptor'. At least four natural compounds  
244 from *Tinospora cordifolia* showed high binding efficacy against SARS-CoV-2 targets involved in  
245 attachment and replication of the virus, hence validating the merit of using *Tinospora cordifolia* in the  
246 clinical management of infection caused by SARS-CoV-2. There is a certain efficacy of natural  
247 compounds from *Tinospora cordifolia* against SARS-CoV-2 protease, surface glycoprotein and RNA  
248 polymerase [21-22]. Extract of *T. chebula* increased spleen lymphocyte proliferation. Based on RT-  
249 PCR analysis, the expression of cytokines (IL-2, IL-10 and TNF- $\alpha$ ), was more in *T. chebula* -treated  
250 than in other control groups [23]. Antioxidant properties of *Piper longum*, *Zinziber officinale* are also  
251 well-known [24,25]. Antiviral activity of Vidanga (*Embelia ribes*) against Influenza virus and  
252 antioxidant activity are well established [26]. Anti-inflammatory, antiviral effects of Yashtimadhu  
253 (*Glycyrrhiza glabra*) are also well-known [27,28]. Shatavari (*Asparagus racemosus*) has many  
254 activities including antioxidant and Immunomodulatory activities [29,30]. Minerals in the drug,  
255 Shankha (incinerated conch shell) Bhasma is helpful to tackle gastric symptoms related to the disease  
256 and Jasath Bhasma (zinc oxide) has an antiviral activity [31]. Jasath Bhasma is the purified zinc from  
257 Ayurvedic process to yield optimum effect of zinc supplementation. Due to antioxidant effects of

258 Zinc, it protects against ROS and RNS. Zinc helps modulate cytokine release and induces  
259 proliferation of T cells and helps to maintain skin and mucosal membrane integrity. Zinc has a central  
260 role in cellular growth and differentiation of immune cells. It is essential for intracellular binding of  
261 tyrosine kinase to T cell receptors, required for T lymphocyte development and activation. Zinc  
262 supports Th1 response [32].

263 When we discuss about the possible mechanism of action, the approach is such that the combination  
264 acts 'as a whole'. There are multiple phyto-ingredients and a lot of chemical entities that act on  
265 multiple targets in various systems of the body. By virtue of such entity-rich drug, a milieu is created  
266 in the body, which is prepared to take care of the infection at multiple levels, organs and systems.  
267 Since it has shown positive results in reducing viral load and immune modulation of TH1 response,  
268 the same herbo-mineral formulation can have role for prophylactic action towards the virus.  
269 Limitation of the study is smaller number of participants.

270 Currently the formulation is known as Capsule CoviLyzer™ and Capsule Abayakasthaa plus<sup>R</sup>, and is  
271 manufactured by Ishaanav Nutraceuticals Pvt. Ltd.

## 272 **CONCLUSION**

273 With COVID-19 pandemic being ongoing in 2021, search for potential antiviral therapies is ongoing.  
274 This polyherbal combination drug was identified to provide effective antiviral activity in mild to  
275 moderate COVID-19 patients. Potential immunomodulatory effects observed with drug can also assist  
276 in preventing inflammatory tissue damage and may help reduce the intensity of systemic  
277 inflammatory syndrome. The investigational drug was found to be safe with no serious adverse event  
278 and it can be safely given along with Standard of Care to enhance its therapeutic activity in patients  
279 with mild to moderate COVID-19 disease for reducing viral load, cytokine storm and clinical

280 recovery. Another study on severely affected Covid patients would be worthwhile to explore of this  
281 formulation, along with the standard of care.

282 **Funding:**

283 The trial was funded by AMAI Trust, Pune

284 **Conflict of interest:**

285 Dr. Suresh Patankar is member of AMAI trust.

286 **Disclosures:**

287 None

288

289 **REFERENCES**

- 290 1. WHO Coronavirus (COVID-19) Dashboard. Available from <https://covid19.who.int/>
- 291 2. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including  
292 Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like  
293 Disease. *Autoimmun Rev.* 2020; 19:102537. Doi:10.1016/j.autrev.2020.102537
- 294 3. Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19: a clue  
295 from innate immunity. *Immunol Res.* 2020; 68:161-168. Doi: 10.1007/s12026-020-09137-5.
- 296 4. Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or  
297 foe?. *Life Sci.* 2020; 256:117900. Doi:10.1016/j.lfs.2020.117900
- 298 5. Leligidowicz A, Feldmann J, Jaye A, Cotten M, Dong T, McMichael A, et al. Direct  
299 relationship between virus load and systemic immune activation in HIV-2 infection. *J Infect*  
300 *Dis.* 2010; 201:114-22. Doi: 10.1086/648733.
- 301 6. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. RECOVERY  
302 Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med.*  
303 2021; 384:693-704. Doi: 10.1056/NEJMoa2021436.

- 304 7. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients  
305 hospitalized with Covid-19 pneumonia. *New England Journal of Medicine*. 2021; 384:20-30.  
306 Doi: 10.1056/NEJMoa2030340.
- 307 8. Kumar S, De Souza R, Nadkar M, Guleria R, Trikha A, Joshi SR, et al. A two-arm,  
308 randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and  
309 safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. *Expert*  
310 *OpinBiolTher*. 2021; 21:675-686. Doi: 10.1080/14712598.2021.1905794
- 311 9. Gautam M, Saha S, Bani S, Kaul A, Mishra S, Patil D, et al. Immunomodulatory activity of  
312 *Asparagus racemosus* on systemic Th1/Th2 immunity: implications for immunoadjuvant  
313 potential. *J Ethnopharmacol*. 2009; 121:241-7. Doi: 10.1016/j.jep.2008.10.028
- 314 10. Vetvicka V, Vetvickova J. Immune enhancing effects of WB365, a novel combination of  
315 *Ashwagandha* (*Withaniasomnifera*) and *Maitake* (*Grifolafrondosa*) extracts. *N Am J Med Sci*.  
316 2011; 3:320-4. Doi: 10.4297/najms.2011.3320
- 317 11. Rangnekar H, Patankar S, Suryawanshi K, Soni P. Safety and efficacy of herbal extracts to  
318 restore respiratory health and improve innate immunity in COVID-19 positive patients with  
319 mild to moderate severity: A structured summary of a study protocol for a randomised  
320 controlled trial. *Trials*. 2020;21:943. Doi: 10.1186/s13063-020-04906-x.
- 321 12. Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. SARS-CoV-2  
322 viral load predicts mortality in patients with and without cancer who are hospitalized with  
323 COVID-19. *Cancer cell*. 2020; 38:661-71. Doi: 10.1016/j.ccell.2020.09.007.
- 324 13. Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et als. Impact of  
325 SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients  
326 with Coronavirus Disease 2019. *Clin Infect Dis*. 2020:ciaa851. Doi: 10.1093/cid/ciaa851..
- 327 14. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective,  
328 randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients

- 329 with COVID-19. *Antimicrobial agents and chemotherapy*. 2020; 64: e01897-20. Doi:  
330 10.1128/AAC.01897-20.
- 331 15. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe  
332 COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2020;  
333 395:1569-1578. Doi: 10.1016/S0140-6736(20)31022-9.
- 334 16. Zhao R, Sun Y, Zhang Y, Wang W, Wang S, Wang C, et al. Distinguishable Immunologic  
335 Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with  
336 Nondiabetic Individuals. *Mediators Inflamm*. 2020; 2020:6914878. Doi:  
337 10.1155/2020/6914878.
- 338 17. Kumar D, Arya V, Kaur R, Bhat ZA, Gupta VK, Kumar V. A review of immunomodulators  
339 in the Indian traditional health care system. *Journal of Microbiology, Immunology and*  
340 *Infection*. 2012; 45:165-84. Doi: 10.1016/j.jmii.2011.09.030
- 341 18. Stephen-Victor E, Das M, Karnam A, Pitard B, Gautier JF, Bayry J. Potential of regulatory T-  
342 cell-based therapies in the management of severe COVID-19. *EurRespir J*. 2020; 56:2002182.  
343 Doi: 10.1183/13993003.02182-2020
- 344 19. Mahmoudi S, Rezaei M, Mansouri N, Marjani M, Mansouri D. Immunologic Features in  
345 Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. *J*  
346 *ClinImmunol*. 2020; 40:974-976. Doi: 10.1007/s10875-020-00824-4.
- 347 20. van Eeden C, Khan L, Osman MS, Cohen Tervaert JW. Natural Killer Cell Dysfunction and  
348 Its Role in COVID-19. *Int J Mol Sci*. 2020; 21:6351. Doi: 10.3390/ijms21176351
- 349 21. Sagar V, Kumar AHS. Efficacy of natural compounds from *Tinosporacordifolia* against  
350 SARS-CoV-2 protease, surface glycoprotein and RNA polymerase. *Virology*. 2020:1-0. Doi:  
351 10.21203/rs.3.rs-27375/v1



- 352 22. Adhikari B, Marasini BP, Rayamajhee B, Bhattarai BR, Lamichhane G, Khadayat K, et al.  
353 Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19:  
354 A review. *Phytother Res.* 2021; 35:1298-1312. Doi: 10.1002/ptr.6893
- 355 23. Aher V, Wahi A. Immunomodulatory activity of alcohol extract of Terminalia  
356 chebularetzcombretaceae. *Tropical Journal of Pharmaceutical Research.* 2011;10(5):567-75.  
357 Doi: 10.4314/tjpr.v10i5.5.
- 358 24. Nahak G, Sahu RK. Phytochemical evaluation and antioxidant activity of Piper cubeba and  
359 Piper nigrum. *Journal of Applied Pharmaceutical Science.* 2011; 1:153-157.
- 360 25. Bekkouch O, Harnafi M, Touiss I, Khatib S, Harnafi H, Alem C, et al. In Vitro Antioxidant  
361 and In Vivo Lipid-Lowering Properties of Zingiberofficinale Crude Aqueous Extract and  
362 Methanolic Fraction: A Follow-Up Study. *Evid Based Complement Alternat Med.*  
363 2019:9734390. Doi: 10.1155/2019/9734390.
- 364 26. Vaghela JS, Sisodia SS. In vitro antioxidant activity of Embeliaribes fruit extracts. *J Global*  
365 *Pharma Technol.* 2011; 3:14-30.
- 366 27. Anagha K, Manasi D, Priya L, Meera M. Scope of Glycyrrhizaglabra (Yashtimadhu) as an  
367 Antiviral agent: A Review. *Int J CurrMicrobiol App Sci.* 2014; 3:657-65.
- 368 28. Asl NN, Hosseinzadeh H. Review of antiviral effects of Glycyrrhizaglabra L. and its active  
369 component, glycyrrhizin. *Journal of Medicinal Plants.* 2007; 6:1-12.
- 370 29. Sharma U, Kumar N, Singh B, Munshi RK, Bhalerao S. Immunomodulatory active steroidal  
371 saponins from *Asparagus racemosus*. *Medicinal Chemistry Research.* 2013; 22:573-9. Doi:  
372 10.1007/s00044-012-0048-4
- 373 30. Karuna DS, Dey P, Das S, Kundu A, Bhakta T. In vitro antioxidant activities of root extract  
374 of *Asparagus racemosus* Linn. *Journal of traditional and complementary medicine.* 2018;  
375 8(1):60-5. Doi: 10.1016/j.jtcme.2017.02.004

- 376 31. Subramani Paranthaman Balasubramani, Padma Venkatasubramanian, Subrahmanya Kumar  
 377 Kukkupuni Bhushan Patwardhan. Plant-based Rasayana drugs from Ayurveda. Chinese  
 378 Journal of Integrative Medicine; 2011; volume 17: pages88–  
 379 94Doi:<https://doi.org/10.1007/s11655-011-0659-5>  
 380 32. Maggini S, Pierre A, Calder PC. Immune Function and Micronutrient Requirements Change  
 381 over the Life Course. Nutrients. 2018; 10:1531. Doi: 10.3390/nu10101531  
 382

383 **Table 1: Baseline characteristics in two groups**

Parameters	SoC + Placebo (n=33)	SoC + IP (n=39)	P value (between groups)
Age (years)	43.0 (34.0 - 58.0)	47.0 (40.0 – 56.0)	0.336
Gender			
Male	20 (60.6)	17 (43.6)	0.150
Female	13 (39.4)	22 (56.4)	

384 Data presented as median (IQR) or n (%); \*SoC = Standard of Care

385

386 **Table 2: Change in viral load in two groups**

Viral load	SoC + Placebo (N=21)	SoC + IP (N=31)	P value (between groups)
Baseline	385670 (30807 to 131511846)	662081 (56904 to 19485712)	0.758
Day 4	66845 (11978 to 836124.5)	48963 (8774 to 1248257)	0.845
P value	0.106	0.002	

388

389

390 **Table 3: Clinical Improvement**

NRS score	SoC + Placebo (n=31)	SoC + IP (n=35)	P value (between groups)
Baseline	4.26±1.09	4.3±1.13	0.781
Follow-up	3.16±1.03	1.74±1.03	<0.0001

P value	<0.0001	<0.0001	
<b>WHO Ordinal Scale</b>	<b>SoC + Placebo (n=31)</b>	<b>SoC + IP (n=35)</b>	
Baseline	1.71 (+0.78)	1.63 (+0.84)	0.58
Follow-up	1.26 (+0.63)	1.03 (+0.77)	0.33
P value	0.03	0.0001	

391

392 **Table 4: Changes in inflammatory and immunological parameters**

Parameters	SoC + Placebo (n=14)	SoC + IP (n=15)	P value (between groups)
<b>Total leucocyte count</b>			
Baseline	6257.1±4488.6	7240.0±2580.4	0.472
Follow-up	7200.0±1669.6	7606.7±1547.5	0.502
Change from baseline	942.6 (3005.0 to -1119.3)	366.7 (1720.2 to -986.8)	
P value	0.341	0.570	
<b>Absolute B cell count</b>			
Baseline	193.4±102.6	255.9±154.7	0.215
Follow-up	317.9±213.5	437.3±270.5	0.200
Change from baseline	124.5 (205.1 to 43.8)	181.4 (282.4 to 80.5)	
P value	0.005	0.002	
<b>Absolute T cell count</b>			
Baseline	710.5±389.4	836.8±455.6	0.431
Follow-up	1512.7±477.8	1720.9±611.7	0.319
Change from baseline	802.2 (1094.5 to 510.0)	884.1 (1230.7 to 537.5)	
P value	<0.0001	<0.0001	
<b>Absolute CD3, CD4 and T helper cells</b>			
Baseline	399.8±239.1	515.5±314.8	0.278
Follow-up	834.8±261.3	1055.7±417.6	0.102
Change from baseline	435.0 (628.1 to 242.1)	540.2 (737.1 to 343.4)	
P value	<0.0001	<0.0001	
<b>Absolute CD3: CD8</b>			
Baseline	270.7±128.6	299.7±183.5	0.629
Follow-up	571.4±195.7	607.3±258.8	0.679
Change from baseline	300.7 (406.1 to 195.4)	307.6 (455.8 to 159.3)	
P value	<0.0001	0.001	
<b>Absolute T<sub>reg</sub> counts</b>			
Baseline	5.9±5.0	6.5±7.1	0.817
Follow-up	3.6±2.7	4.8±2.9	0.244
Change from baseline	-2.3 (0.35 to -5.1)	-1.7 (2.1 to -5.3)	
P value	0.082	0.358	
<b>Absolute NK Cell count</b>			
Baseline	10.4±9.0	9.9±11.4	0.898
Follow-up	17.6±9.5	28.3±32.5	0.248
Change from baseline	7.2 (13.0 to 1.3)	18.3 (38.1 to -1.5)	


P value	0.020	0.067	
<b>Neutrophils (%)</b>			
Baseline	63.7±16.6	63.9±17.1	0.969
Follow-up	54.4±7.9	51.7±9.3	0.422
Change from baseline (95% CI)	-9.3 (-1.5 to -17.0)	-12.2 (-2.6 to -21.9)	
P value	0.023	0.017	
<b>Absolute neutrophil count</b>			
Baseline	4457.1±4597.1	4615.4±2562.2	0.914
Follow-up	3985.7±1346.1	4046.1±1158.0	0.902
Change from baseline (95% CI)	-3555.4 (1581.4 to -2524.3)	-569.3 (799.3 to -1937.8)	
P value	0.628	0.383	
<b>Lymphocyte (%)</b>			
Baseline	25.7±12.6	27.2±14.7	0.776
Follow-up	32.8±7.1	37.0±7.0	0.135
Change from baseline (95% CI)	7.1 (13.7 to 0.5)	9.8 (18.5 to 1.1)	
P value	0.036	0.031	
<b>Absolute lymphocyte counts</b>			
Baseline	1250.0±462.7	1653.8±773.1	0.109
Follow-up	2342.9±734.5	2846.1±810.0	0.103
Change from baseline (95% CI)	1092.9 (1515.0 to 670.7)	1192.3 (1698.8 to 685.8)	
P value	<0.0001	<0.0001	
<b>Th cell response</b>	<b>SoC + Placebo</b>	<b>SoC + IP</b>	
<b>Ab Th1</b>			
Baseline	209.5 (45.3 to 419.8)	164 (27 to 501)	0.861
Follow-up	347 (215.8 to 529.3)	430 (235 to 683)	0.338
P value for change	0.098	0.023	
<b>Ab Th2</b>			
Baseline	143 (66.5 to 230)	164 (80 to 398)	0.318
Follow-up	424 (343.7 to 593.8)	593 (351 to 768)	0.338
P value for change	0.005	0.003	
<b>Antibody levels</b>	<b>SoC + Placebo</b>	<b>SoC + IP</b>	
<b>IgG</b>			
Baseline	1301.4±284.9	1593.6±309.5	0.015
Follow-up	1132.3±223.9	1356.6±260.5	0.021
Change from baseline (95% CI)	-169.1 (-42.9 to -295.4)	-237.0 (-79.9 to -394.1)	
P value	p=0.012	p=0.007	
<b>IgM</b>			
Baseline	117.7±77.2	98.8±40.6	0.438
Follow-up	113.0±62.9	89.9±28.4	0.420
Change from baseline (95% CI)	-4.7 (8.2 to -17.5)	-8.9 (8.8 to -26.7)	
P value	p=0.450	p=0.295	
<b>COVID Antibodies</b>	<b>Placebo</b>	<b>Drug</b>	
	5.1±2.5	6.0±2.7	0.353

393

394

395 **Figure Legends**

396 **Image 1: Treatment administration in two groups**



397

398

399 **Figure 1: Consort Study flow Chart**

400

401

